Evidence map›Paper›PMID 39085227›Full record

ArticleBlood cancer journal2024

Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms.

Dragan Jevremovic, Min Shi, Pedro Horna, Gregory E Otteson, Michael M Timm, Linda B Baughn, Patricia T Greipp, Wilson I Gonsalves, Prashant Kapoor, Morie A Gertz and 9 more

Abstract readLetter
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Dragan JevremovicDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA. Jevremovic.Dragan@mayo.edu.ORCID 0000-0002-1792-5822
Min ShiDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5741-4293
Pedro HornaDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-4909-6157
Gregory E OttesonDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Michael M TimmDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Linda B BaughnDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5229-4897
Patricia T GreippDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5536-9011
Wilson I GonsalvesDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Prashant KapoorDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-4342-364X
Morie A GertzDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-3853-5196
Moritz BinderDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9014-9658
Francis K BuadiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Jiehao ZhouDepartment of Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Scottsdale, AZ, USA.
Angela DispenzieriDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8780-9512
Taxiarchis KourelisDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8573-9434
Eli MuchtarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2210-2174
S Vincent RajkumarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5862-1833
Shaji K KumarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5392-9284
Horatiu OlteanuDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5783-4485

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
Assessment of Metabolites Among Asymptomatic Precursor and Malignant Monoclonal GammopathiesR01CA254961 · NCI · MAYO CLINIC ROCHESTER · PI GONSALVES, WILSON · 2021 to 2024
$1.5M
NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA254961U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50 CA186781-4U.S. Department of Health & Human Services | NIH | NIH Clinical Center (Clinical Center) CA254961
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Flow CytometryNeoplasm, ResidualNeoplasms, Plasma CellAgedFemaleHumansMaleMiddle AgedSensitivity and Specificity

Identifiers

PMID39085227
PMCPMC11291477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.